Physician profile
John Wallace Neville
NPI 1265492797
$8,559.30
in general payments reported to CMS, 2019-2025
48 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $238 · 2021: $347 · 2022: $1,381 · 2023: $1,693 · 2024: $1,590 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,328.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,214.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,137.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $890.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $763.56 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $499.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.35 | 2019-2025 | Xifaxan |
| Amgen INC. | $313.08 | 2019-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $312.46 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.10 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $270.07 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $209.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $194.88 | 2019-2025 | Verquvo, Capvaxive, Gardasil |
| Pfizer INC. | $189.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $174.55 | 2019-2023 | |
| Amarin Pharma, INC. | $174.16 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Neville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.